What We're Reading: Page 207
Industry reads hand-picked by our editors
Feb 24, 2020
Feb 21, 2020
-
Philadelphia Business Journal
Spark Therapeutics co-founder Dr. Katherine High departing
-
STAT
In a cramped Kendall Square, biotech startups squeeze into shared labs
-
POLITICO
Problems with CDC coronavirus test delay expanded U.S. screening
-
The Boston Globe
Drop in cancer deaths reflect failures of our society. Really
Feb 20, 2020
Feb 19, 2020
-
The Boston Globe
Founder of Medford biotech who defrauded investors of $7.5m gets 7 years in prison
-
BioCentury
The Phase III trials and pharma sales most likely to be disrupted by COVID-19
-
OneZero
The Price of DNA Sequencing Dropped From $2.7 Billion to $300 in Less Than 20 Years
-
Pittsburgh Business Times
Mylan-Upjohn merger filings contemplate coronavirus impact
Feb 18, 2020
-
The Wall Street Journal
Gilead’s Coronavirus Drug Trial Slowed by Lack of Eligible Recruits
-
C&EN
Could an NLRP3 inhibitor be the one drug to conquer common diseases?
-
The New York Times
Payout From a National Opioids Settlement Won't Be as Big as Hoped
-
STAT
'Pharma doesn’t like fish oil': Wall Street funds sold Amarin after big win with heart drug
Feb 14, 2020
-
Regulatory Focus
Internal FDA Emails Reveal How Price, Sanders's Pressure Played a Role in Competitor's Approval, Catalyst Claims
-
Endpoints News
Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine
-
Reuters
Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials
Feb 13, 2020
-
The Wall Street Journal
Coronavirus-Drug Development Becomes a Top Focus at Gilead
-
New England Journal of Medicine
The Magic of Randomization versus the Myth of Real-World Evidence
-
Bloomberg
Elizabeth Holmes Gets Fraud Case Narrowed, Not Dismissed
Previous
